Highlights Prime Medicine, Inc.

Equities

PRME

US74168J1016

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
7.45 ^USD	-7.22%		+10.21%	-15.91%

20/05	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target	MT
17/05	North American Morning Briefing : The "Everything -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : The "Everything -2-	17/05	DJ
Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Earnings Flash (PRME) PRIME MEDICINE Reports Q1 Revenue $591,000	10/05	MT
Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance	29/04	MT
Prime Medicine Announces FDA Clearance of Investigational New Drug Application for PM359 for the Treatment of Chronic Granulomatous Disease	29/04	CI
Prime Medicine 2023 Net Loss Narrows	01/03	MT
Prime Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Prime Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	04/11	CI
Prime Medicine's Q3 Loss Narrows	04/11	MT
Prime Medicine, Inc. Presents First-Ever Prime Editing Data in Non-Human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-Causing Mutation of Gsd1b	27/23/27	CI
Prime Medicine, Inc. Presents First in Vivo Proof-Of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases	24/23/24	CI
Prime Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
MaxCyte strikes deal; Barkby sells Workshop	01/23/01	AN
Prime Medicine, Cimeio Therapeutics Unveil Research Partnership to Improve Treatment of Genetic Diseases	22/23/22	MT
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs(Tm) for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome	22/23/22	CI
Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Prime Medicine Reports Q4 Net Loss; Says Cash Sufficient to Fund Expenses Into 2025	09/23/09	MT
Prime Medicine, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	09/23/09	CI
Prime Medicine Completes Upsized $175 Million IPO	25/22/25	MT
Prime Medicine Announces Closing of Upsized Initial Public Offering	25/22/25	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prime Medicine, Inc.

Equities

PRME

US74168J1016

Highlights

Filters